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Background aims. Immunomagnetic enrichment of CD34þ hematopoietic “stem” cells (HSCs) using paramagnetic nano-
bead coupled CD34 antibody and immunomagnetic extraction with the CliniMACS plus system is the standard approach to
generating T-cell-depleted stem cell grafts. Their clinical beneﬁcence in selected indications is established. Even though
CD34þ selected grafts are typically given in the context of a severely immunosuppressive conditioning with anti-thymocyte
globulin or similar, the degree of T-cell depletion appears to affect clinical outcomes and thus in addition to CD34 cell
recovery, the degree of T-cell depletion critically describes process quality. An automatic immunomagnetic cell processing
system, CliniMACS Prodigy, including a protocol for fully automatic CD34þ cell selection from apheresis products, was
recently developed. We performed a formal process validation to support submission of the protocol for CE release, a
prerequisite for clinical use of Prodigy CD34þ products. Methods. Granulocyte-colony stimulating factoremobilized
healthy-donor apheresis products were subjected to CD34þ cell selection using Prodigy with clinical reagents and con-
sumables and advanced beta versions of the CD34 selection software. Target and non-target cells were enumerated using
sensitive ﬂow cytometry platforms. Results. Nine successful clinical-scale CD34þ cell selections were performed. Beyond
setup, no operator intervention was required. Prodigy recovered 74  13% of target cells with a viability of 99.9 0.05%. Per
5  10E6 CD34þ cells, which we consider a per-kilogram dose of HSCs, products contained 17  3  10E3 T cells and 78
 22  10E3 B cells. Conclusions. The process for CD34 selection with Prodigy is robust and labor-saving but not time-
saving. Compared with clinical CD34þ selected products concurrently generated with the predecessor technology, prod-
uct properties, importantly including CD34þ cell recovery and T-cell contents, were not signiﬁcantly different. The
automatic system is suitable for routine clinical application.
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CD34þ selected allogeneic stem cell grafts are used for
patients at very high risk of severe graft-versus-host dis-
ease because of poor human leukocyte antigenmatching
(speciﬁcally in the haplo-identical setting), patients
intolerant to immunosuppressants or those with non-
malignant diseases who will not beneﬁt from immuno-
logical graft-versus-leukemia effects [1e5]. CD34þCorrespondence: Halvard Bönig, DRK-BSD, Sandhofstrasse 1, 60528 Frankfur
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body (AB) and a single-use tubing systemwithmagnetic
column. The protocol consists of successive platelet
depletion, AB incubation, magnetic selection and col-
umnelution/formulation.TheT-cell depletion achieved
with this method is so profound that very sensitive ﬂow
cytometry protocols are required for residual T-cell
enumeration. Although semi-manual and complex, the
process is of sufﬁcient robustness to consistently
generate clinical products for transplantation. Labor
consumption is considerable, almost 4 hours,more than
3 hours of which require the presence of two operators.
Recently, a protocol was introduced for the automatic
cell manipulator CliniMACS Prodigy, which shares
important components with CliniMACS Plus and in
principle performs the same protocol as CliniMACS
Plus, but fully automatically.This protocolwas validated
with research mobilized apheresis products under full-
scale clinical conditions to generate data for submis-
sion for regulatory approval/CEmarking.Data from this
validationarepresentedandcomparedagainstdata from
CliniMACS Plus products, which were concurrently
generatedby the sameoperators and thequality ofwhich
was assessed with the same ﬂow cytometry platform.Methods
Donors and cells
Granulocyte-colony stimulating factoremobilized
apheresis products were collected from healthy vol-
unteers who had undergone apheresis for unrelated
donor stem cell donation [13] and had agreed to
extend the apheresis for the purposes of this valida-
tion. Written informed donor consent was collected.
The study was performed in agreement with the
Helsinki declaration with ethics committee approval
(ethics committee of Johann Wolfgang Goethe Uni-
versity Medical Center, Frankfurt, protocol #486/
13). Aphereses were performed with standard Ter-
umo mononuclear cell apheresis equipment as pre-
viously described [14,15], not to exceed a total
apheresis duration (clinical graft plus validation
product) of 300 min. Target hematocrit was <4 mg/
dL. Apheresis products containing 4.75  0.5 
10E10 (mean  SEM; range: 2.3e7.2  10E10)
white blood cells with 4.8  0.6  10E8 (mean 
SEM; range: 2.3e7.6  10E8) CD34þ cells and 38
 5% (mean  SEM; range: 7e51%) neutrophil
content were used. Apheresis collections and selec-
tions were done in the second quarter of 2014.Hemocytometry
Leukocyte concentrations in starting population,
non-target population and target population weredetermined using the Sysmex XT1800 automatic
hemocytometer for plausibility control against the
single-platform ﬂow cytometry assays. Flow cytom-
etry was performed with FACSCalibur and
LSRFortessa (Becton-Dickinson). Cells were
stained with 7-AAD viability dye (BD Biosciences)
and the following antibodies (all from BD Bio-
sciences unless otherwise noted): anti-CD45-FITC
(2D1)/anti-CD34-PE (8G12) (BD Stem Cell
Reagent), anti-CD14-V450 (M4P9), anti-CD3-
APC (SK7), anti-CD4-AmCyan (SK3), anti-CD8-
APC-Vio770 (BW135/80, Miltenyi Biotec),
anti-CD20-APC-eFluor780 (2H7, eBioscience) and
anti-CD56-PE-Cy7 (CMSSB, eBioscience). In-vitro
diagnostic-grade ABs were used where possible.
Three platforms each were tested on apheresis
product, positive and negative fraction (the com-
mercial single-platform stem cell enumeration
(SCE) kit; BD Biosciences), our clinical routine
single-platform residual T-cell detection panel and a
second residual cell identiﬁcation panel designed for
extended characterization of non-CD34þ cells for
the purpose of these studies. The ﬁrst two platforms
were formally validated, are described in standard
operating procedures and were performed in accor-
dance with those procedures; the residual T-cell
detection panel, in addition to containing BD
counting beads for single-platform T-cell enumera-
tion, includes CD34 and CD45 AB and ISHAGE
(International Society for Hematology and Graft
Engineering, now ISCT, International Society for
Cellular Therapy)-conforming gating for bona ﬁde
CD34þ cells, to allow for additional cross-
validation/plausibility control against the robust
and simple three-color SCE protocol [16]. The
extended research panel, including additional
quantiﬁcation of CD20 and CD56 and ISHAGE-
conforming gating for CD34þ cell enumeration,
was not formally validated to GMP level, but results
were similarly compared against the two other,
formally validated panels. Given the demonstrable
precision of CD34þ cell enumeration, whenever the
CD34þ cell count with any of the residual cell
panels differed from the count with SCE by 10%,
the measurement had to be repeated. Unless other-
wise indicated, all cell concentrations, frequencies or
numbers refer to 7AAD-negative (viable) cells only.Selection reagents and consumables
The CliniMACS Prodigy device [17,18], Prodigy
TS310 tubing sets, CliniMACS CD34 Reagent (2
vials) and CliniMACS PBS/EDTA buffer were
received from Miltenyi Biotec. NaCl 0.9%, H2O
injectionem and human serum albumin (HSA) were
from Baxter.
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The principle of immunomagnetic CD34 selection
with nanobead-conjugated CD34 antibodies was ﬁrst
described 20 years ago by Shpall and colleagues [19].
Of the multitude of competing methods available at
the time, only the Miltenyi system continues to be in
use today [6,20]. In principle, the process remains
unchanged, although a progression of increasingly
user-friendly devices for the extraction of immuno-
magnetically labeled cells have become available.
CliniMACS Prodigy is the most recent device in this
succession. Magnet and reagent being the same as for
the predecessor technology, the same apheresis
product speciﬁcations (upper limits for total white
blood cells [1.2 10E11] or total CD34þ cells [1.2
10E9] per two vials of reagent and TS310 tubing set
as used in this validation) are applied to Prodigy and
CliniMACS Plus. In these studies, because the small-
scale (one reagent) separation protocol is not yet
available, for all selections, two vials of CD34 reagent
were used; that is, CD34 selection reagent was slightly
“overdosed.” After booting the Prodigy device, the
CD34 selection protocol is selected, and the tubing
set installed as directed by the user interface. Liquid
reagents, including two vials of CD34 reagent, and
apheresis product are connected as directed. An
advanced beta version of the large-scale CD34 selec-
tion software was used; the CD34 selection package
on Prodigy is currently not yet CE-marked (CE mark
is expected in the second quarter of 2015 on the basis
of the data presented here), and thus none of the cell
products were intended for clinical use. Without
making relevant changes to the established process for
CliniMACS Plus [12], Prodigy successively and fully
automatically performs platelet washes, CD34 AB-
nanobead conjugate incubation, immunomagnetic
column selection and cell elution. The speciﬁcation of
the allogeneic CD34-selected CliniMACS Plus
product, for which our institution holds a marketing
authorization, stipulates, in addition to being non-
infectious with a panel of blood-transmissible agents
as directed by the German Transfusion Act and
bioburden-negative, a viable CD34þ cell dose in
excess of 4  10E6/kg and a viable CD3þ cell dose
below 5  10E4/kg of the recipient in at least 90% of
products. B-cell content must be measured and
declared. Shelf life is 72 h from the end of the
apheresis, by which time the product must have been
either infused or cryopreserved. Additional quality
controls for the purposes of this validation include
immunological differentiation of additional non-
CD34þ cells (i.e., natural killer cells, monocytes
and granulocytes), as well as assessment of product
stability over time. CD34þ cell recovery and log-
depletion of T cells are routinely calculated as mea-sures of process quality. The goal of this validation
exercise was to generate nine successive products
meeting the regulator-approved speciﬁcation of
CD34-selected allogeneic stem cell products.Statistics
Data were entered into Microsoft Excel spreadsheets
fromwhichdescriptive statisticswere extracted.LogT-
cell depletion was calculated as the negative logarithm
to base 10 of number of total T cells in the ﬁnal product
divided by the number of T cells in the apheresis
product. Results from eight concurrently performed
clinical CD34 selections on CliniMACS Plus and ﬂow
cytometrically analyzed with the same residual T-cell
platform served as informal comparator; Student’s t-
test was used to identify statistically signiﬁcant differ-
ences betweenCliniMACSPlus andProdigy products;
signiﬁcance was assumed at P < 0.05.Results
Process and process stability
In total, nine Prodigy runs were performed. Runs were
initiated between 1 and 18 h after the end of the apher-
esis. Initial instrument setupwith preparation and sterile
connection of buffers and cells as well as installation of
the tubing setwere uneventful and took approximately 1
h of continuous operator hands-on time.Thereafter, the
in total 5.75-h-long Prodigy process began, after which
performance of quality control assays (described earlier)
and product clearance can begin. Overnight processing
without operators in attendance is in principle feasible,
and some processes were performed in this fashion.
Guidance during setup and operation by the
touchscreen graphic user interface was ﬂawless and easy
to follow; kit installation and deinstallation required
minimal training. Except that potentially the wrong
ﬂuids could be connected to the ports, which the ma-
chine would not detect, there is little room for handling
errors and complex checks test kit installation and kit
integrity. Process steps requiring operator intervention
(typically in the presence of a second operator), operator
supervision (one operator) or running automatically are
drawn to a time axis in Figure 1; for comparison, the
CliniMACS Plus process is depicted.Product properties
Prodigy products contained 3.5 0.5 10E8 (mean
SEM) (range: 1.5e5.9  10E8) leukocytes, of which
3.4  0.5  10E8 (mean  SEM) (purity mean 
SEM: 93.9 0.8%; range: 89.5e97.9%)wereCD34þ
cells and 9.4  1.3  10E5 (mean  SEM; range:
Figure 1. Comparative schedules of the CD34 selection process
with CliniMACS Plus and CliniMACS Prodigy. White, gray and
black bars: column height depicts time, shading marks manual,
automatic-supervised and autonomous preparation steps, respec-
tively. Process time is similar for both protocols, but hands-on time
with Prodigy is much reduced.
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60%CD4þ and 40%CD8þ. This reﬂected a recovery
of 74  13% (mean  SEM; range: 49.3e100%) of
CD34þ cells and a depletion of 99.99  0.0% of T
cells. Starting with a T-cell content of 24  4 T cells
per CD34þ cell (mean  SEM), products had a
CD34þ to T-cell ratio of 390  67 (mean  SEM;
range: 144e830). The T-cell depletion achieved with
Prodigy as calculated with the most frequently used
formula (seeMethods) was 4 log (mean SEM: 9.7
10E-5  7.7  10E-6, range: 1.21  10E-4e6.6 
10E-5). Considering 5  10E6 CD34þ cells/kg a
typical clinical transplant dose, a recipient would have
received 16.6 2.9 10E3 (range: 6e34.6 10E3) T
cells/kg, a dose well within the speciﬁcation (50 
10E3/kg) of the licensed allogeneic CD34-selectedstem cell product. Additional product properties are
shown in Table I. Figure 2 demonstrates selected
panels from a representative ﬂow cytometric analysis of
apheresis product, non-target (negative fraction) and
target populations.
To establish at the same time optimal storage
conditions and shelf life, as well as freezability, ali-
quots of product were stored at 4C for 24e72 h in
0.5e5% HSA and subsequently analyzed for viable
CD34þ cell recovery using the SCE kit. Surprisingly,
HSA concentrations of 0.5% were associated with the
highest recovery, 81  9% and 78  8% after 48 and
72 h. Detailed stability data are shown in Figure 3.
Aliquots of CD34-selected cells stored in 5% HSA
were also supplemented 24 h after the apheresis end
(to mimic a worst-case clinical scenario for cryopres-
ervation) with cryo-medium to a ﬁnal concentration of
50% saline with 5% w/v HSA, 40% X-Vivo10 and
10% dimethyl sulfoxide and frozen in controlled-rate
freezers. After at least 24 h in storage at 145C, an
aliquot was thawed and subjected to viable CD34þ
cell enumeration. Of the viable CD34þ cells con-
tained in the aliquot collected immediately pre-freeze
(71  7% of that immediately after the end of the
process), 82  14% were recovered post-thaw. Thus,
stability of Prodigy-processed CD34þ cells for the
speciﬁed shelf life as well as suitability for freeze-
thawing was documented.Discussion
This formal validation exercise of the new fully
automatic CD34þ cell selection process with nine
full-scale mobilized apheresis products on the
CliniMACS Prodigy device was performed under
routine clinical conditions, even though none of the
cell products were slated for clinical use. Results
therefore can be immediately translated into clinical
routine. Indeed these data concurrently served as
validation runs, which the manufacturer submitted
for approval of the CE mark from the national
authority for the CD34 process on Prodigy. The
“process” consists of the reagents that are the same as
those used for the CD34 process on the CliniMACS,
the Prodigy consumable (tubing set) and the speciﬁc
CD34 selection software. As reported, the entire
process proceeded ﬂawlessly without unscheduled
operator intervention.
Analysis of the target population reveals a
depletion factor (ratio of T cells after and before
selection) that is slightly inferior, albeit not statisti-
cally, to that achieved with concurrently performed
clinical CliniMACS Plus CD34 processes. Howev-
er, as a result of how donors for the validation study
were selected, the T-cell frequency was much lower
(by about half) in the Prodigy cohort. This variable
Table I. Properties of apheresis products and CD34-selected cell products generated there from by CliniMACS Prodigy (experimental) or
concurrent CliniMACS Plus (clinical) (meanSEM).
CliniMACS Prodigy CliniMACS Plus
Apheresis product
WBC (total) 4.75  0.5  10E10 5.35  0.8  10E10
CD34þ 4.78  0.6  10E8 4.12  0.5  10E8
CD3þ 9.58  0.8  10E9 2.04  0.3  10E10
CD4þ 6.01  0.5  10E9 —
CD8þ 3.13  0.2  10E9 —
CD14þ 1.19  0.08  10E10 —
CD20þ 2.08  0.3  10E9 —
CD56þ 1.59  0.3  10E9 —
CD34þ frequency 1.21  0.26% 0.63  0.04%
CD34þ viability 99.85  0.06% 99.96  0.04%
Post-selection
WBC (total) 3.54  0.5  10E8 3.06  0.3  10E8
CD34þ 3.42  0.5  10E8 2.93  0.3  10E8
CD3þ 9.44  1.3  10E5 3.18  1.7  10E5
CD4þ 5.42  0.8  10E5 —
CD8þ 3.35  0.5  10E5 —
CD14þ 1.22  0.4  10E6 —
CD20þ 3.64  0.5  10E6 —
CD56þ 4.04  1.2  10E5 —
CD34þ frequency 93.87  0.84% 95.96  1.23%
CD34þ viability 99.85  0.05% 99.78  0.08%
CD34þ recovery 73.6  13.2% 72.4  2.8%
CD3þ/5  10E6 CD34þ 16.6  2.9  10E3 9.01  5.8  10E3
CD3þ depletion 9.7  10E-5  7.7  10E-6 4.2  10E-5  3.1  10E-5
CD20þ/5  10E5 CD34þ 7.79  2.2  10E4 —
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although independent of the selection technology.
Clearly, the suggested modest advantage of
CliniMACS Plus with respect to the depletion
factor (9.7  10E-5  7.7  10E-6 for Prodigy
versus 4.2  10E-5  3.1  10E-5 for CliniMACS
Plus, P ¼ 0.14) is only partly due to this imbalance
between starting materials. The hypothetical “per
kilogram” T-cell dose that a recipient would have
received, assuming a stem cell dose of 5  10E6/kg
BW, also trended toward higher values with Prodigy
(16.6  2.9  10E3) than with CliniMACS (9.0 
5.8  10E3, P ¼ 0.3). Because the number of T
cells in the product is higher for Prodigy, the
average recipient would receive more T cells or, if a
more stringent limit for T cells is assumed, e fewer
CD34þ cells/kg than with a CliniMACS Plus
product. Why ﬁnal product variability with respect
to recovery was greater with the automatic method
than with the semi-automatic predecessor technol-
ogy is not clear; it is apparent that the operator has
no inﬂuence over this outcome. The markedly
higher neutrophil content of the starting apheresis
material might be partly responsible because neu-
trophils are known to negatively affect both purity
and recovery of immunomagnetic methods. Alter-
natively, platelet contamination has been reported
to affect purity and recovery; data generated duringthe development of the CD34 selection protocol on
Prodigy conﬁrm, however, that the three successive
automatic platelet washes on Prodigy remove
50e70% of platelets, which is similar to the efﬁ-
ciency of the CliniMACS manual platelet washes.
As is apparent from Figure 1, Prodigy only
minimally reduces process time over CliniMACS
Plus, but the hands-on operator time is reduced by
almost 2 h. Because the Prodigy process could run
unsupervised or supervised remotely overnight, a
possible advantage would be avoidance of unfavor-
able working hours while recovering cells of maximal
freshness and, hence, functional quality, given that
experience shows approximately linear cell loss over
time, starting from the moment that the cells are
collected from the donor [21]. The process of CD34
selection is maximally simpliﬁed by Prodigy.Conclusions
This is the ﬁrst report on the CD34 selection process
on CliniMACS Prodigy. As we have shown,
CliniMACS Prodigy is unconditionally suitable to
perform the CD34 selection process; all nine valida-
tion products met the pre-deﬁned speciﬁcation of the
licensed cell product G-CSF mobilized allogeneic
HPCs, CD34 selected, German Red Cross Blood
Service Baden-Württemberg-Hessen. Recovery of
Figure 2. Quality analysis of Prodigy-generated CD34 selected products: partial depiction of residual T-cell enumeration by ﬂow cytometry.
The representative example shows in the apheresis product a sevenfold excess of T cells over CD34þ cells; the ﬁnal product contains 1400
CD34þ cells for every T cell, yielding a T-cell depletion factor relative to the target cells of 10E-4 (4 log).
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automatic method. Final product content of poten-
tially allo-reactive T cells was modestly higher, albeit
not statistically; preliminary studies indicate that it
could be further improved by more copious ﬂushingFigure 3. Stability of Prodigy-generated CD34 products in
different media: stability data for CD34þ cells in 0.5e10%HSA in
saline stored at 4e8C for 48 h or 72 h after the end of the
apheresis are shown. Data present the concentration of viable
CD34þ cells recovered at the indicated time points as percent of
the concentration measured immediately post-manufacturing.
Stability is excellent for the entire observation time; it is best
preserved in HSA 0.5% in saline.of the column and the complex tubing system.
Prodigy reduces operator time by approximately half.
Once all other cell products currently generated on
CliniMACS Plus can be similarly produced on
Prodigy, regulatory approval processes are completed
and an open software permitting cell therapy labora-
tories “programming” their own cell processing pro-
cesses becomes available, CliniMACS Prodigy can
replace CliniMACS Plus in cell processing facilities.
Although in principle it is simple enough for any
transplant unit to use, the quality control (residual T-
cell quantiﬁcation) is demanding and will limit the
technology to a ﬁnite number of centers of excellence.
Because, as we have shown, Prodigy products are
quite stable when refrigerated, worldwide shipping
from a small number of sites would be conceivable.Acknowledgments
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